Introduction {#s1}
============

It has been known for years that coronary artery disease (CAD) and myocardial infarction (MI) are the main killers in the world. The pathogenesis of CAD and MI involves important inflammatory components [@pone.0088152-Topol1], [@pone.0088152-Wu1]. One of the critical steps of inflammatory processes is the migration of leukocytes from the vessel wall to atherosclerosis lesion[@pone.0088152-Ross1], which is strictly regulated by a variety of cell adhesion molecules and leukocyte-activating factors[@pone.0088152-Springer1]. Leukocytes is captured from the blood stream and then rolled along the endothelial cell surface. The process is mediated by the selectins, a special family of three cell adhesion molecules: P-selectin, E-selectin and L-selectin. The three selectins have fundamental differences in their distribution, activation and expression. E-selectin is only expressed on the activated endothelium and recruits polymorphonuclear leukocytes, myeloid cells and T-lymphocytes to the inflammation sites[@pone.0088152-Vestweber1]; P-selectin is expressed on the endothelial cells as well as platelets and instantly migrates to the plasma membrane when exposed to some free radicals, nitric oxide synthase inhibitors and other mediators[@pone.0088152-Lefer1]; L selectin is expressed on most types of leukocytes, as well as some neutrophils and myeloid cells [@pone.0088152-Vestweber1] and serves as a homing receptor for lymphocytes to peripheral lymph nodes. L-selectin recruits cells to inflammation lesion like E-selectin.

Although the in vivo study has suggested that E-selectin and P-selectin exert similar effects of leukocyte adhesion on atherosclerosis lesions. The exact roles of E-selectin and P-selectin remain unclear. Estimates have placed genetic predisposition to be responsible for 40--60% of susceptibility to CAD [@pone.0088152-Wu1], [@pone.0088152-Roberts1]--[@pone.0088152-Wu3]. The single nuclear polymorphisms (SNPs) of adhesion molecules act independently of known risk factors of severe atherosclerosis [@pone.0088152-Wenzel1]. Several polymorphisms of the selectin genes have been mentioned to contribute to the CAD incidence. For instance, an adenine to cytosine substitution at cDNA position 561, resulting in an amino acid exchange from serine (Ser) to arginine (Arg), in the epidermal growth factor (EGF) -like domain of E-selectin has profound effects on atherosclerosis. In additional, a Thr715Pro polymorphism located in front of the transmembrane domain of the *P-selectin* gene is associated with the susceptibility to CAD and MI. These two polymorphisms were the most investigated, but with conflicting results. It should be considered that the sample size in the previous studies was relatively small. Hence, the studies had low statistical power to detect modest associations of genotype with CAD. To shed some light on this divergence and maximize statistical power, we sought to evaluate the correlation of these two polymorphisms of the selectin genes with CAD by performing a comprehensive meta-analysis of available individual studies. Furthermore, the between-study heterogeneity and the publication bias were addressed.

Materials and Methods {#s2}
=====================

Data Source and Search Strategy {#s2a}
-------------------------------

We followed the guidelines of the 2009 preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement [@pone.0088152-Moher1] when performed the literature search ([Checklist S1](#pone.0088152.s001){ref-type="supplementary-material"}). The search strategy was conducted by searching from PubMed/MEDLINE, Embase, China Nation Knowledge Infrastructure (CNKI) Platform and Wanfang electronic databases up to October 2013. In addition, five Japanese electronic databases (PORTA, GeNii, CiNii, J-STAGE and Google Scholar \[Japanese\]) as well as three Korean electronic databases (Nurimedia, Koreanstudies Information Service System \[Kiss\] and Google Scholar \[Korean\]) were also retrieved. The following medical subject heading (MeSH) terms and key words were used in the computer-based searches: 'Ser128Arg' or 'A561C', 'E-selectin' or 'SELE', 'Thr715Pro' or 'rs6136', 'P-selectin' or 'SELP' and 'coronary artery disease' or 'acute coronary syndrome' or 'myocardial infarction' or 'atherosclerosis '. We scanned the titles and abstracts of potentially appropriate articles followed by determining whether these studies conformed to our inclusion criteria. If the suitability of a study was uncertain, we scrutinized the full text for further estimation. We identified additional studies by screening the bibliographies of relevant studies and reviews. The related search function of Pubmed was also used.

Selection Criteria {#s2b}
------------------

All the studies conformed to the following criteria were potentially involved: (1) Studies followed case-control or cross-sectional design (studies without controls were excluded); (3) Studies providing adequate allele or genotype information on the examined polymorphisms; (4) Studies published in English journals or their supplements; (5) If multiple studies derived from a common population, only the study with the largest sample size was extracted to avoid overlapping data; (6) The genotype frequency amongst control must conform to Hardy-Weinberg equilibrium (HWE).

Standard definitions were used to diagnosis disease outcomes [@pone.0088152-Vach1].CAD was defined as significant stenosis with ≥50% luminal obstruction in at least one or more major coronary vessel [@pone.0088152-Wright1]. Acute coronary syndrome (ACS) was defined by unstable angina pectoris and fatal or non-fatal MI [@pone.0088152-Joensen1] and MI was defined by the World Health Organization (WHO) criteria [@pone.0088152-Anderson1].

Data Extraction {#s2c}
---------------

Two authors (Z.W. and Y.Lou.) independently extracted the relevant information from qualified studies by the standard data-collection protocol according to the inclusion criteria. The data were entered into separate databases in duplicate by the two authors. Any encountered inconsistencies were resolved at a consensus meeting. The following data was gathered based on different cohort: first author\'s name, publication year, ethnicity, geographic location, study design, population source, disease outcomes, matching variables, clinical characteristics (such as gender, age, body mass index \[BMI\], the percentage of hypertension \[HTN\], diabetes mellitus \[DM\], smoking status), the distribution of the Ser128Arg and Thr715Pro genotype in both patients and controls and conformity to genotype frequencies with HWE. Continuous variables were manifested as mean ± standard deviation (SD) or median (5th and 95th percentiles).

Statistical Analysis {#s2d}
--------------------

Data management and processing were performed using Review Manager software release 5.0 (Oxford, England) and Stata 11.0 (Stata Corporation, College Station, Texas, USA). The combined odd ratios (ORs) corresponding to 95% confidence intervals (CIs) were calculated under the random-effects model using DerSimonian & Laird method. Considering the relatively low number of homozygote genotype, we only estimate the effect size of these two polymorphisms on CAD under the allelic and dominant models. The possibility of heterogeneity was assessed using Cochran\'s chi-square based Q statistic test [@pone.0088152-Lau1] and index I^2^ statistic. A significant Q statistic test (P\<0.10) indicated heterogeneity among studies. I^2^ = 100%×(Q−df)/Q, measures the proportion of the between-study variability due to heterogeneity rather than chance[@pone.0088152-Higgins1], [@pone.0088152-Higgins2]. Departure from HWE was examined via the chi-square test or Fisher\'s exact test on the basis of a Web program (<http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl>).

A univariate meta-regression was used to explore potential factors associated with the genetic heterogeneity. A cumulative meta-analysis might indicate the influence of the initial published research on subsequent studies and the evolution of the combined estimates with ascending date of publication. A sensitivity analysis was conducted using one-study removal approach to identify the influence of each study on the overall effect size [@pone.0088152-Biros1]. The possibility of publication bias could be visual by an funnel plot [@pone.0088152-Egger1] and then assessed by the Egger\'s and the Begg-Mazumdar test as well as the trim-and-fill method. All P values were 2-sided. P\<0.05 was considered significant except the Q statistic test.

Result {#s3}
======

Literature Search {#s3a}
-----------------

A total of 395 relevant citations were reviewed based on our selection strategy. The stepwise selection process is shown in [Figure 1](#pone-0088152-g001){ref-type="fig"}. After sequent selection, a total of 19 articles (10 of the *E-selectin* Ser128Arg polymorphism and 9 of the *P-selectin* Thr715Pro polymorphism) with adequate information satisfied our inclusion criteria. The study by Morgan *et al.* [@pone.0088152-Morgan1] provided the genotype information of both the two polymorphism and regarded ACS as the disease endpoint. Because the population of the study by Volcik *et al.* [@pone.0088152-Volcik1] derived from two different ethnic backgrounds (Caucasian & African), we considered them as two independent studies and calculated the ORs separately. The Indian population of the study by Tripathi *et al.* [@pone.0088152-Tripathi1] was regarded as an independent group because its lineage is miscellaneous and cannot simply be grouped as Asian or Caucasian [@pone.0088152-Reich1]--[@pone.0088152-Palanichamy1]. In general, 15 studies were performed among Caucasians [@pone.0088152-Morgan1], [@pone.0088152-Volcik1], [@pone.0088152-Barbaux1]--[@pone.0088152-Zak1] and 2 among Asians [@pone.0088152-Yoshida1], [@pone.0088152-Li1]. Most of the studies used a retrospective case-control design [@pone.0088152-Morgan1], [@pone.0088152-Tripathi1], [@pone.0088152-Barbaux1]--[@pone.0088152-Kee1], [@pone.0088152-Sakowicz1]--[@pone.0088152-Li1] except 2 studies[@pone.0088152-Volcik1], [@pone.0088152-Rosner1].P-B controls were adopted in 8 studies[@pone.0088152-Volcik1], [@pone.0088152-Barbaux1], [@pone.0088152-Bugert1], [@pone.0088152-Carter1], [@pone.0088152-Herrmann1]--[@pone.0088152-Rosner1], [@pone.0088152-Wenzel2] and H-B in 10 studies[@pone.0088152-Morgan1], [@pone.0088152-Tripathi1], [@pone.0088152-Endler1], [@pone.0088152-Ghazouani1], [@pone.0088152-Sakowicz1], [@pone.0088152-Ye1]--[@pone.0088152-AbuAmero2]. Cases and controls were matched in 8 studies [@pone.0088152-Morgan1], [@pone.0088152-Tripathi1], [@pone.0088152-Carter1], [@pone.0088152-Ghazouani1]--[@pone.0088152-Rosner1], [@pone.0088152-Wenzel2]. CAD was employed as the disease endpoint in 12 of the studies [@pone.0088152-Volcik1], [@pone.0088152-Tripathi1], [@pone.0088152-Barbaux1]--[@pone.0088152-Ghazouani1], [@pone.0088152-Wenzel2]--[@pone.0088152-Zak1], [@pone.0088152-Li1], while MI was taken as the outcome in 5 studies [@pone.0088152-Herrmann1]--[@pone.0088152-Sakowicz1], [@pone.0088152-Yoshida1].

![Flowchart diagram illustrating search strategy and study selection.](pone.0088152.g001){#pone-0088152-g001}

Data Synthesis {#s3b}
--------------

There were 10 studies with 3,369 CAD patients and 2,577 controls for the *E-selectin* Ser128Arg polymorphism and 10 studies with 5,886 cases and 18,345 controls for the *P-selectin* Thr715Pro polymorphism involved in our meta-analysis. The clinical characteristics of included studies are shown in [Table 1](#pone-0088152-t001){ref-type="table"}. The allele and genotype frequencies of these two polymorphisms are listed in [Table 2](#pone-0088152-t002){ref-type="table"} and [3](#pone-0088152-t003){ref-type="table"} respectively. All the studies conformed to HWE (P~HWE~\>0.05).

10.1371/journal.pone.0088152.t001

###### Summary of all included studies in the meta-analysis.

![](pone.0088152.t001){#pone-0088152-t001-1}

  First Author    Year   Ethnicity   Geographic location      Design       Source   Endpoints   Matched    Status      Age,year     Gender,M(%)   HTN,%   DM,%    Smoke,%     BMI,kg/m^2^
  -------------- ------ ----------- --------------------- --------------- -------- ----------- --------- ---------- -------------- ------------- ------- ------- --------- ------------------
  Abu-Amero KK    2007   Caucasian          Saudi          Retrospective    H-B        CAD        no       cases      54.2±11.9        69.0       83.7    91.6     30.9          --^a^
                                                                                                          controls    55.7±11.8        55.7       62.8    67.2     44.7            --
  Barbaux SC      2001   Caucasian         Germany         Retrospective    P-B        CAD        no       cases      62.3±10.2        74.1        --      --      23.9         26.9±3.7
                                                                                                          controls     61.3±7.5        70.4        --      --      13.5         26.6±5.0
  Bugert P        2004   Caucasian         Germany         Retrospective    P-B        CAD        no       cases      59.5±16.9        74.3       52.1    13.8     34.8            --
                                                                                                          controls    54.4±17.1        51.4        0.0     --       --             --
  Carter AM       2003   Caucasian           UK            Retrospective    P-B        CAD        yes      cases      59(52--65)       65.0       32.0     8.0     74.0     26.7(26.2--27.1)
                                                                                                          controls    63(49--67)       56.0       15.0     1.0     41.0     25.5(25.0--25.9)
  Endler G        2003   Caucasian         Austria         Retrospective    H-B        CAD        no       cases      64(57--74)       69.2       62.7    100.0    37.3     27.6(25.0--29.8)
                                                                                                          controls    64(56--75)       56.5       50.7    100.0    15.9     27.7(23.6--30.9)
  Ghazouani L     2011   Caucasian         Tunisia         Retrospective    H-B        CAD        yes      cases      58.2±11.7        78.2       38.1    52.7     41.4         27.3±4.3
                                                                                                          controls    56.5±14.5        76.1       12.3     9.1     21.5         25.3±2.4
  Herrmann SM     1998   Caucasian        France&UK        Retrospective    P-B        MI         yes      cases       54.0±8.2        100.0       --      --       --             --
                                                                                                          controls     53.0±8.5        100.0       --      --       --             --
  Kee F           2000   Caucasian           UK            Retrospective    P-B        MI         yes      cases         57.2          56.2        --      --      79.3           27.5
                                                                                                          controls       58.1          55.0        --      --      61.4           26.8
  Li Y            2002     Asian            China          Retrospective    H-B        CAD        no       cases      62.1±10.6        67.7        --      --      54.4         24.8±3.1
                                                                                                          controls    60.5±11.7        66.8        --      --      29.7         24.0±3.6
  Morgan TM       2007   Caucasian           US            Retrospective    H-B        ACS        yes      cases     60.7±12.5(M)      67.8       60.1    23.8     33.1       29.1±5.5(M)
                                                                                                                     63.1±13.2(F)                                             29.9±6.9(F)
                                                                                                          controls   60.0±12.1(M)      60.6       51.2    11.9     13.2       27.9±5.0(M)
                                                                                                                     61.8±12.8(F)                                             27.7±6.9(F)
  Rosner SA       2005   Caucasian           US             Prospective     P-B        MI         yes      cases       58.7±8.6        100.0      25.1     5.6     15.1         25.5±3.3
                                                                                                          controls     58.8±8.5        100.0      15.2     2.7     15.3         25.0±3.0
  Sakowicz A      2009   Caucasian         Poland          Retrospective    H-B        MI         no       cases       41.0±4.9        83.4       38.0     0.0     87.1            --
                                                                                                          controls     54.0±8.6        47.1       15.0     0.0     58.6            --
  Tripathi R      2009    Indian            India          Retrospective    H-B        CAD        yes      cases       57.1±9.7        79.0       47.4    43.2     20.1         25.5±3.0
                                                                                                          controls     53.2±9.2        74.0       23.0    24.8     10.0         25.1±3.1
  Volcik KA       2006   Caucasian           US             Prospective     P-B        CAD        no       cases       55.6±3.9        66.0       47.0    24.0     34.0         28.2±3.9
                         & African                                                                        controls     53.8±5.7        41.0       32.0     9.0     25.0         27.6±5.7
  Wenzel K        1997   Caucasian         German          Retrospective    P-B        CAD        yes      cases      42(25--50)       87.6       46.9     6.2     89.4            --
                                                                                                          controls        38           90.3        --      --       --             --
  Ye SQ           1999   Caucasian           US            Retrospective    H-B        CAD        no       cases          --           57.3        --      --       --             --
                                                                                                          controls        --           45.1        --      --       --             --
  Yoshida M       2003     Asian            Japan          Retrospective    H-B        MI         no       cases       57.7±8.1        76.3        --      --       --             --
                                                                                                          controls     47.6±7.9        70.0        --      --       --             --
  Zak I           2008   Caucasian         Poland          Retrospective    H-B        CAD        no       cases       43.8±6.1        66.5        --      --      55.5         26.8±4.3
                                                                                                          controls    35.3±10.5        75.9        --      --      23.2         24.8±3.7

P-B:population-based study; H-B:hospital-based study; CAD: coronary artery disease; MI: myocardial infarction; ACS: acute coronary syndrome; M(%):male(percent); F:female; HTN: hypertension; DM: diabetes mellitus; BMI: body mass index; ^a^:data not available; Age and BMI are expressed as mean ±SD (standard deviation) or median (5th and 95th percentiles)

10.1371/journal.pone.0088152.t002

###### The frequencies of the *E-selectin* Ser128Arg polymorphism among CAD and controls.

![](pone.0088152.t002){#pone-0088152-t002-2}

  First Author    Sample size   Arg allele,%   Ser allele,%   ArgArg genotype   SerArg genotype   SerSer genotype    HWE                                  
  -------------- ------------- -------------- -------------- ----------------- ----------------- ----------------- ------- ---- ----- ----- ------ ------ ------
  Abu-Amero KK       1112           427            6.4              6.4              93.6              93.6         --^a^   --   --    --     --     --   
  Endler G            185            69            11.4            13.0              88.6              87.0           3     0    36    18    146     51    0.21
  Li Y                248           256            6.7              3.1              93.3              96.9           0     0    33    16    215    240    0.61
  Morgan TM           811           650            9.4             10.3              90.6              89.7           7     6    137   123   658    528    0.69
  Sakowicz A          163           140             --             14.3               --               85.7          --     5    --    29    116    102    0.12
  Tripathi R          329           331            8.5              5.6              91.5              94.4           0     0    56    37    273    294    0.28
  Wenzel K            113           103            15.5             8.7              84.5              91.3           1     2    33    14     79     87    0.13
  Ye SQ               82             71            19.5            10.6              80.5              89.4           2     0    28    15     52     56    0.32
  Yoshida M           135           327            6.3              3.4              93.7              96.6           0     0    17    22    118    305    0.53
  Zak I               191           203            12.0            10.8              88.0              89.2           4     2    38    40    149    161    0.78
  Total              3369           2577           8.7              7.7              91.3              92.3          17     15   378   314   1806   1824  

HWE: Hardy--Weinberg equilibrium. The P-value of HWE determined by the χ^2^ test or Fisher\'s exact test among controls; ^a^:data not available.

10.1371/journal.pone.0088152.t003

###### The frequencies of the *P-selectin* Thr715Pro polymorphism among CAD and controls.
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  First Author               Sample size   Pro allele,%   Thr allele,%   ProPro genotype   ThrPro genotype   ThrThr genotype   HWE                                    
  ------------------------- ------------- -------------- -------------- ----------------- ----------------- ----------------- ----- ----- ----- ------ ------ ------- ------
  Barbaux SC                     869           334           --^a^             --                --                --          --    --    --     --    634     255   
  Bugert P                       261           214            13.2             9.6              86.8              90.4          7     3    55     35    199     176    0.41
  Carter AM                      249           252            10.3            10.4              89.7              89.6          3     2    45     48    199     201    0.64
  Ghazouani L                    298           339            2.5              4.1              97.5              95.9          0     0    17     24    319     267    0.46
  Herrmann SM                    647           758            8.9             12.5              91.1              87.5          4    14    99    136    501     507    0.18
  Kee F                          696           647            11.7            14.1              88.3              85.9          8    10    138   155    512     455    0.44
  Morgan TM                      811           650            10.4             9.8              89.6              90.2          9     2    150   124    646     530    0.06
  Rosner SA                      522           2089           9.8             10.1              90.2              89.9          3    21    96    380    423    1688    0.94
  Volcik KA \[African\]          337           3657           2.3              2.2              97.7              97.8          0     1    14    138    296    3043    0.66
  Volcik KA \[Caucasian\]       1196           9405           11.5            11.1              88.5              88.9         16    113   224   1802   876    7243    0.94
  Total                         5886          18345           9.7              9.3              90.4              90.7         50    166   838   2842   4605   14365  

HWE: Hardy--Weinberg equilibrium. The P-value of HWE determined by the χ^2^ test or Fisher\'s exact test among controls; ^a^:data not available.

The overall frequency of the *E-selecitn* 128Arg allele was 8.7% in cases and 7.7% in controls. The frequency of the 128Arg allele among Caucasians (9.0% cases & 9.0% controls) was moderately higher than that among Asians (6.5% cases & 3.3% controls). As for the *P-selectin* Thr715Pro polymorphism, most of the qualified studies were performed among Caucasians except one study (Volcik *et al.*\[African\] [@pone.0088152-Volcik1]). The 715Pro allele proportion in cases (9.7%) was similar to that in controls (9.3%).

[Table 4](#pone-0088152-t004){ref-type="table"} and [5](#pone-0088152-t005){ref-type="table"} summarized the estimates of genotype data for allelic and dominant models in total and subgroup analysis. In the main analyses, the overall comparison of the *E-selectin* 128Arg allele relative to 128Ser yielded a significantly increased risk of CAD (allele comparison: P = 0.02, OR = 1.33, 95%CI 1.04--1.69, P~heterogeneity~ = 0.01; dominant model: P = 0.02, OR = 1.40, 95%CI 1.06--1.87, P~heterogeneity~ = 0.02) with remarkable heterogeneity([Figure 2a](#pone-0088152-g002){ref-type="fig"}); No predominant association was observed for the *P-selectin* Thr715Pro polymorphism with CAD under the both allelic (P = 0.40, OR = 0.94, 95%CI 0.82--1.08, P~heterogeneity~ = 0.03) and dominant model(P = 0.22, OR = 0.92, 95%CI 0.82--1.05, P~heterogeneity~ = 0.10) ([Figure 2b](#pone-0088152-g002){ref-type="fig"}).

![Forest plots detailing the association of the *E-selectin* Ser128Arg polymorphism (Arg versus Ser, Figure 2a) and the *P-selectin* Thr715Pro polymorphism (Pro versus Thr, Figure 2b) with CAD using the allelic model in overall analysis.](pone.0088152.g002){#pone-0088152-g002}
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###### Summary estimates of the *E-selectin* Ser128Arg polymorphism with the CAD risk under the allelic and dominant models.
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  study population             study number,   Allele comparison (Arg versus Ser)   Dominant model(ArgArg+SerArg versus SerSer)                                                                
  --------------------------- --------------- ------------------------------------ --------------------------------------------- ------------ ------- ------ ------ ------ ------------ ------ ------
  *[Total studies]{.ul}*       10(3369/2577)                  0.02                                     1.33                       1.04--1.69   59.6    0.01   0.02   1.40   1.06--1.87   62.5   0.02
                                                                                                                                                                                               
  *[Ethnicity]{.ul}*                                                                                                                                                                           
  Asian                         2(383/583)                    0.00                                     2.07                       1.33--3.24    0.0    0.77   0.00   2.16   1.37--3.40   0.0    0.76
  Caucasian                    7(2657/1663)                   0.33                                     1.13                       0.88--1.45   49.0    0.08   0.27   1.20   0.87--1.66   57.9   0.04
                                                                                                                                                                                               
  *[Matched]{.ul}*                                                                                                                                                                             
  Yes                          3(1253/1084)                   0.25                                     1.33                       0.82--2.15   75.8    0.02   0.05   1.42   0.80--2.51   49.3   0.08
  No                           7(2116/1493)                   0.06                                     1.35                       0.98--1.85   54.3    0.05   0.23   1.42   1.00--1.99   80.3   0.01
                                                                                                                                                                                               
  *[Disease endpoint]{.ul}*                                                                                                                                                                    
  CAD                          7(2260/1460)                   0.02                                     1.38                       1.06--1.80   50.1    0.06   0.02   1.54   1.09--2.19   53.4   0.02
  MI                            2(298/467)                    0.05                                     1.93                       1.01--3.70   --^a^    --    0.13   1.47   0.89--1.43   31.0   0.13
                                                                                                                                                                                               
  *[Publication Date]{.ul}*                                                                                                                                                                    
  \<2007                        5(763/826)                    0.00                                     1.68                       1.18--2.40   38.8    0.16   0.00   1.68   1.18--2.40   38.8   0.16
  ≥2007                        5(2606/1751)                   0.53                                     1.07                       0.86--1.34   39.0    0.18   0.53   1.07   0.86--1.34   39.0   0.18

a:Test for overall effect; CAD: coronary artery disease; MI: myocardial infarction; ^a^:data not available.

10.1371/journal.pone.0088152.t005

###### Summary estimates of the *P-selectin* Thr715Pro polymorphism with the CAD risk under the allelic and dominant models.
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  study population             study number,    Allele comparison (Pro versus Thr)   Dominant model(ProPro+ThrPro versus ThrThr)                                                               
  --------------------------- ---------------- ------------------------------------ --------------------------------------------- ------------ ------ ------ ------ ------ ------------ ------ ------
  *[Total studies]{.ul}*       10(5886/18345)                  0.40                                     0.94                       0.82--1.08   53.1   0.03   0.22   0.92   0.82--1.05   39.3   0.10
                                                                                                                                                                                               
  *[Design]{.ul}*                                                                                                                                                                              
  Prospective                  3(2055/15151)                   0.74                                     1.02                       0.91--1.14   0.0    0.85   0.73   1.02   0.90--1.16   0.0    0.94
  Retrospective                 7(3831/3194)                   0.38                                     0.91                       0.72--1.13   64.9   0.01   0.14   0.88   0.73--1.05   47.0   0.08
                                                                                                                                                                                               
  *[Source]{.ul}*                                                                                                                                                                              
  P-B                          8(4777/17356)                   0.46                                     0.94                       0.80--1.10   57.3   0.03   0.27   0.93   0.80--1.06   43.2   0.09
  H-B                           2(1109/989)                    0.62                                     0.87                       0.50--1.51   64.6   0.09   0.54   0.85   0.50--1.43   59.8   0.12
                                                                                                                                                                                               
  *[Matched]{.ul}*                                                                                                                                                                             
  Yes                           6(3223/4735)                   0.09                                     0.87                       0.74--1.02   46.5   0.10   0.06   0.86   0.74--1.01   32.3   0.19
  No                           4(2663/13610)                   0.30                                     1.09                       0.93--1.27   8.0    0.34   0.77   1.03   0.86--1.23   24.9   0.26
                                                                                                                                                                                               
  *[disease endpoint]{.ul}*                                                                                                                                                                    
  CAD                          6(3210/14201)                   0.65                                     1.04                       0.87--1.25   24.5   0.26   0.87   0.99   0.83--1.17   25.6   0.24
  MI                            3(1865/3494)                   0.04                                     0.81                       0.67--0.99   49.2   0.14   0.05   0.82   0.67--1.00   44.6   0.16
                                                                                                                                                                                               
  *[Publication Date]{.ul}*                                                                                                                                                                    
  \<2005                        5(2722/2205)                   0.50                                     0.91                       0.68--1.21   69.8   0.02   0.19   0.87   0.70--1.07   49.7   0.09
  ≥2005                        5(3164/16140)                   0.77                                     1.02                       0.92--1.13   0.0    0.53   0.89   1.01   0.90--1.13   0.0    0.59

:Test for overall effect; P-B:population-based; H-B:hospital-based; CAD: coronary artery disease; MI: myocardial infarction.

Sensitivity Analysis {#s3c}
--------------------

Sensitivity analyses demonstrated that no single study influenced the heterogeneity and ORs when evaluating the association between the *E-selectin* Ser128Arg polymorphism and CAD in total analysis. As for the *P-selectin* Thr715Pro polymorphism, the study by Herrmann *et al*.[@pone.0088152-Herrmann1] contributed to the observed heterogeneity in total analysis. The overall heterogeneity no longer existed (P~heterogeneity~  = 0.21) after removing this study and the effect size did not change materially.

Cumulative Analysis and Publication Bias {#s3d}
----------------------------------------

Cumulative trends for allelic contrast of these two polymorphisms suggested there was not any distinct evidence for the first published study that triggered the ensuing replication of other studies that tried to replicate this initial result (data not shown).The funnel plot for the Ser128Arg polymorphism was distinct asymmetric for small negative studies. The Egger\'s (P = 0.041) and the Begg-Mazumdar (P = 0.016) test suggested a presence of publication bias. By using the trim and fill method, we found that if the publication bias was the sole source of the funnel plot asymmetry, 3 studies were needed to be symmetrical ([Figure 3a](#pone-0088152-g003){ref-type="fig"}). For the Thr715Pro polymorphism, the funnel plot analysis as well as the Egger\'s and the Begg-Mazumdar test reflected a low probability of publication bias under the allele comparison (P = 0.91 for Egger\'s test and P = 0.92 for Begg-Mazumdar test) ([Figure 3b](#pone-0088152-g003){ref-type="fig"}).

![Filled Begg\'s funnel plot for studies investigating the effect of the *E-selectin* Ser128Arg polymorphism on CAD (Figure 3a) and Begg\'s funnel plot analysis of the *P-selectin* Thr715Pro polymorphism with CAD risk (Figure 3b).\
Red squares are missed studies due to publication bias in Figure 3a.](pone.0088152.g003){#pone-0088152-g003}

Subgroup Analysis {#s3e}
-----------------

To evaluate the possible factors that contributed to the majority of heterogeneity, we undertook a set of subgroup analyses. ORs generated for the Ser128Arg polymorphism were statistically significant among Asians (allele comparison: P = 0.001, OR = 2.07, 95%CI 1.33--3.24, P~heterogeneity~ = 0.77) but not among Caucasians (allele comparison: P = 0.33, OR = 1.13, 95%CI 0.88--1.45, P~heterogeneity~ = 0.08) ([Figure 4](#pone-0088152-g004){ref-type="fig"}); When data were stratified according to disease type, there was a significant association of the Ser128Arg polymorphism with CAD observed (allele comparison: P = 0.02, OR = 1.38, 95%CI 1.06--1.80, P~heterogeneity~ = 0.06; dominant model: P = 0.02, OR = 1.54, 95%CI 1.09--2.19, P~heterogeneity~ = 0.02); The 128Arg allele carriers had a marginal risk increase (42%) of CAD in matched studies under the dominant model (P = 0.05, 95%CI 0.80--2.51, P~heterogeneity~ = 0.08). Data were then stratified according to publication year. The out points of the publication year (2007 for the *E-selectin* Ser128Arg polymorphism & 2005 for the *P-selectin* Thr715Pro polymorphism) were chosen as the median. Risk increase in the studies published before 2007 (allele comparison: P = 0.004, OR = 1.68, 95%CI 1.18--2.40, P~heterogeneity~ = 0.16) was significantly different from that in the studies published in/after 2007(allele comparison: P = 0.53, OR = 1.07, 95%CI 0.86--1.34, P~heterogeneity~ = 0.18) ([Table 4](#pone-0088152-t004){ref-type="table"}).

![ORs and 95%CI of individual studies and pooled data for the association between the *E-selectin* Ser128Arg polymorphism and CAD among Asians under the allele comparison (Arg versus Ser, Figure 4a) and under the dominant model (ArgArg+SerArg versus SerSer, Figure 4b).](pone.0088152.g004){#pone-0088152-g004}

As for the *P-selectin* Thr715Pro polymorphism, the 715Pro carriers had a significant 19% risk reduction in MI group (allele comparison: P = 0.04, 95%CI 0.67--0.99, P~heterogeneity~ = 0.14) and a suggestive risk effect in CAD group (allele comparison: P = 0.65, OR = 1.04, 95%CI 0.87--1.25, P~heterogeneity~ = 0.26) ([Figure 5](#pone-0088152-g005){ref-type="fig"}). In addition, we observed a marginal association of the Thr715Pro polymorphism with CAD in matched studies (allele comparison: P = 0.09, OR = 0.87, 95%CI 0.74--1.02, P~heterogeneity~ = 0.10; dominant model: P = 0.06, OR = 0.86, 95%CI 0.74--1.01, P~heterogeneity~ = 0.19). However, there is a lack of dramatic association of the Thr715Pro polymorphism with CAD risk when data were categorized according to study design (prospective/retrospective), population source (P-B/H-B) and publication date (\<2005/≥2005)([Table 5](#pone-0088152-t005){ref-type="table"}).

![Meta-analysis for the association between the *P-selectin* Thr715Pro polymorphism and MI under the allele comparison (Pro versus Thr, Figure 5a) and under the dominant model (ProPro+ThrPro versus ThrThr, Figure 5b).](pone.0088152.g005){#pone-0088152-g005}

Meta-regression Analysis {#s3f}
------------------------

A univariate meta-regression analysis was used to detect the effect of potential factors on genetic heterogeneity. Single covariates such as ethnicity, population source, case definition, study design, matching information, language, publication year and the baseline characteristics of total population were added in a series of univariate models. There was no evidence suggesting these factors were responsible for the between-study heterogeneity for both the *E-selectin* Ser128Arg polymorphism and the *P-selectin* Thr715Pro polymorphism.

Discussion {#s4}
==========

There has been growing interest in the role of cellular adhesion molecules in atherosclerosis. Among these, the selectins play essential roles in the first step in leukocyte recruitment and infiltration, which is vital in the key process of atherosclerosis[@pone.0088152-Ross1]. The association between the SNPs of the selectin genes with CAD was previously confounding because of contradictory results produced by a range of relatively small individual studies. In addition, true variability across different population[@pone.0088152-Lohmueller1] and different genetic backgrounds[@pone.0088152-Salanti1] may be the other explanations. Meta-analysis is an ideal tool to identify the genuine association while addressing between-study heterogeneity. To clarify this issue, we performed a meta-analysis of publicly independent studies. To our best knowledge, this is the first meta-analysis appraising the relationship of the selectin genes with CAD risk. As a result, we detected that carrier status for the *E-selectin* 128Arg allele was significant associated with an increase of 33% in CAD risk with remarkable heterogeneity. We hypothesized the ethnicity may be a potential origin of between-study heterogeneity. The subgroup analysis suggested that the risk increase of the Ser128Arg polymorphism on CAD among Asians were dramatically larger than Caucasians. Although the minor allele frequency of the Ser128Arg polymorphism was slightly different between Asians and Caucasians, this inconsistence can be attributed to the pleiotropic effect of the Ser128Arg polymorphism due to various genetic ancestral backgrounds. Different linkage disequilibrium patterns due to different populations were likely to be another explanation. A SNP may be in close linkage with another nearby causal variant in one ethnic population but not in another. Ethnicity might be a source of between-study heterogeneity for the Ser128Arg polymorphism. However, we were unable to evaluate the influence of ethnicity on the CAD risk of the *P-selectin* 715Pro carriers, because most of the eligible studies concerning the Thr715Pro polymorphism were conducted among Caucasians. It is difficult to estimate the modest association in other racial descents unless examining a larger population. Constructing optimized databases and replicating the results of these two polymorphisms related to CAD in different populations may benefit to draw definitive conclusions.

As well as the obvious impact of ethnicity, distinct heterogeneity can be observed when comparing different disease types (e.g., CAD versus MI). Although both CAD and MI most commonly result from atherosclerotic occlusion of the coronary arteries and share many of the same inflammatory factors, the pathological manifestations of CAD and MI are quite different. Acute atherosclerotic plaque disruption with thrombosis, which compromises coronary blood flow, is the key process of MI[@pone.0088152-Ross1]. Although some effects on leukocyte adhesion of the E- selectin and P-selectin are overlapping, these two members of the selectin family may partly differ in function. Besides the first adhesive cellular step, E-selectin also mediates the immune response of injured endothelial cells[@pone.0088152-Haller1]. E- selectin binding to the sialylated Lewis^x^ antigen (sLe^x^) is regarded as the preliminary step of endothelial activation, damage or turnover and serves as a molecular marker for atherosclerosis [@pone.0088152-Hwang1].Reduction in the expression of E-selectin protects against atherosclerosis in apolipoprotein E-deficient mice [@pone.0088152-Collins1]. We identified a strong susceptibility of the Ser128Arg polymorphism to disease outcome in CAD. Substitution of E-selectin EGF domain residue 128Ser with an arginine results in an alternation in E-selectin protein ligand binding specificity and an enhanced adherence of monocyte and neutrophil to the activated endothelium in vascular areas [@pone.0088152-Yoshida1], [@pone.0088152-Revelle1]. The bound and activated leukocytes and the cytokine mediators exacerbate atherosclerosis progression. By contrast, the *P-selectin* Thr715Pro polymorphism exhibited as a significant protect factor of MI but not CAD. It is could be a likely explanation if the protective effect of the 715Pro allele was directed against thrombosis rather than atherosclerosis[@pone.0088152-Herrmann1]. P-selectin is localized in storage granules of platelets and the Weibel-Palade bodies of endothelial cells. P-selectin can interact with P-selectin glycoprotein ligand 1(PSGL-1) expressed on leukocytes and triggers the synthesis of pro-coagulatory tissue factor and the subsequent release of tissue factor positive microparticles from leukocytes[@pone.0088152-Andre1]. This is a key process of atherothrombosis. The Thr715Pro polymorphism, located 15 amino acids in front of the transmembrane domain, is a non-conservative amino acid exchange. The 715Pro impairs terminal glycosylation of P-selectin and has poor sensitivity of glycan-modifying Golgi enzymes, which then lead to affect the export of P-selectin on the cell surface and inefficient adhesion compared to the wild-type [@pone.0088152-Subramanian1]. The less P-selectin molecules result in the generation of fewer platelet-monocyte aggregates. This could probably explain the protective effect of the Thr715Pro polymorphism on MI. However, the true functional significance of these two polymorphisms in vivo remains unclear. Further studies assessing the selectin proteins expression and regulation are required to clarify the problem.

Our study still has several limitations. First, only two of the most common SNPs of the selectin genes were investigated. We could not rule out the possible influence of other rare variations or uncommon SNPs that have not been extensively studied. Considering the effect of a SNP on a multi-factorial disease such as CAD is relatively weak, particular haplotypes involving the Ser128Arg polymorphism or another functional mutation in linkage disequilibrium may have more significance. Another problem should be cautiously considered. There was evidence for the publication bias of the *E-selectin* Ser128Arg polymorphism in the meta-analysis. This is said to occur when the chance of the publication of a smaller study increases if it shows a stronger effect [@pone.0088152-Rucker1]. By contrast, the small negative results tend to be rejected for publication. We cannot rule out the possibility of language bias and the influence of publication timing. It is likely that some unpublished studies and "grey" literature (articles in languages other than English) have not been included. Larger and well-design studies from different language databases are required to ascertain the robustness of our results.

In summary, our meta-analysis expanded previous individual studies by supporting the evidence that the *E-selectin* Ser128Arg polymorphism was associated with an increased risk of CAD while the *P-selectin* Thr715Pro polymorphism could be a protective factor of MI. We suggested that the members of selectin family appear to play heterogeneous roles at the development of atherosclerosis and therefore be new candidate targets for diagnostic purposes and therapeutic interventions in atherosclerosis.
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